This first, prospective, peer reviewed scientific evaluation of vascular access complications after large bore cardiovascular procedures demonstrated extremely low rates of vascular access and bleeding complications with the MANTA closure device. 50 patients were treated resulting in 1 VARC-2 major complication and zero VARC-2 minor complications. The mean and median Time to Hemostasis was 2 minutes 23 seconds and 24 seconds respectively with 74% of patients having hemostasis in <1 minute. The authors noted that the results compared extremely favorably to outcomes observed with currently used methods.
William W. O’Neill, M.D., Chairman of the Scientific Advisory Board at Essential Medical, Inc., and Medical Director of the Center for Structural Heart Disease at Henry Ford Hospital in Detroit commented: “The device is extremely easy to use compared to current methods. The results of this study and ‘real world’ registry data emerging from commercialization in Europe are extraordinarily encouraging.”
Closure of large bore femoral access sites has been associated with significant morbidity including higher rate of complications and higher total cost of care. A recent JAMA Cardiology publication (doi:10.1001/jamacardio.2017.0265) demonstrated the need for a reliable large bore closure device to reduce the current 17.7% bleeding complication seen and unsettling costs. Compared to median total health care costs of $29,968 for patients without bleeding complications, median total health care costs were $48,663 for patients with bleeding complications. As demonstrated in the European study data, MANTA’s fail-safe deployment provides rapid and reliable hemostasis with low complication rates, with great potential to minimize these aforementioned bleeding complication implications.
MANTA is a novel CE Marked vascular closure device that is commercially available in the Netherlands. It is designed to close punctures ranging from 10F to 25F at femoral arterial access sites after cardiac catheterization procedures such as transcatheter aortic valve replacement (TAVR), endovascular treatment of abdominal aortic aneurysms (AAA/EVAR), ventricular assist (VAD), and balloon aortic valvuloplasty (BAV). An IDE study is currently underway in the US.
About Essential Medical
Essential Medical, Inc., is a privately held company focused both on evolving the small bore market and transforming the large bore vascular closure market by delivering products that meet the unmet need for fast closure without complications. The company was founded in 2010 by Greg Walters, a senior product development executive with 25 years’ experience creating innovative cardiovascular products, and Dr. Gary Roubin, MD, PhD, a coronary and carotid stenting pioneer.
SOURCE Essential Medical, Inc.